DS Biopharma and Equateq Ltd today announced a strategic agreement that provides DS Biopharma with synthetic lipids for the next phase of its DS107 clinical development program.
Equateq will manufacture DS Biopharma’ specific active lipids, at Equateq’s cGMP API plant located in the Western Isles of Scotland. The terms of the agreement were undisclosed.
Jonathan D. Rowe, Ph.D., Head of Intellectual Property and Portfolio Strategy for DS Biopharma stated, ” DS107 is a very promising therapy that DS Biopharma intends to rapidly bring to market. With the supply of DS107 active pharmaceutical ingredient secured, DS Biopharma looks forward to commencing the next phase of the DS107 acne clinical program.”
Adam Kelliher, Equateq CEO and founder, said: “We have been very impressed by DS’s understanding of the immense potential of synthetic lipids for various therapeutic applications, and we are in a strong position to support their current and future development plans with a robust supply of the active ingredient in DS107.”
Equateq is a privately-owned lipid production company based in the Western Isles of Scotland, where its facility has been concentrating lipids for nearly 30 years. Equateq is fully cGMP compliant, as certified by the UK’s health authority, the MHRA, and for manufacturing lipid APIs, uses its Maxomega™ technology. This concentration method is based on advanced HPLC separation, and allows Equateq to deliver specific lipid APIs at up to 99% purity at commercial scale.
DS107 is a topical formulation of a semi-synthetic fatty acid. DS107 is currently being studied for use in treating acne and atopic dermatitis.
About DS Biopharma
DS Biopharma, a privately held biopharmaceutical company, was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life for people with diseases for which current therapies are unsatisfactory. DS Biopharma is led by recognized experts in developing fatty acids, including their bioactive derivatives, for the treatment of human disease.
DS Biopharma: email@example.com, +35312933590
Updated from Dignity Sciences to DS Biopharma as of 11th May 2015